Patent Application
20180200335
The present invention relates to suppressors of B cell activation, therapeutic agents for autoimmune diseases, and medical kits comprising the therapeutic agents. More specifically, the present invention relates to suppressors of B cell activation comprising TGF-beta 3, and therapeutic agents for autoimmune diseases that use the suppressors. Furthermore, the present invention relates to therapeutic agents for autoimmune diseases that comprise a molecule formed by linking TGF-beta 3 with an antibody or an antibody fragment. The present invention also relates to medical kits comprising the above-mentioned therapeutic agents.
Autoantibodies are known to induce various autoimmune diseases, including systemic lupus erythematosus (SLE), which is characterized by severe inflammation in multiple organ systems (Non-Patent Document 1). The high-affinity autoantibodies primarily originate from self-reactive B cells that underwent somatic hypermutation in germinal centers (GCs) (Non-Patent Document 2). Follicular helper T (TFH) cells expressing CXCR5 are helper T cells functionally specialized to provide help to B cells allowing the formation of GCs and the subsequent long-lived plasma cell differentiation. Therefore, regulation of the quality and quantity of TFH cells and memory B cell populations in GCs is closely associated with pathology of autoimmune diseases. CD4+CD25+ regulatory T cells (CD25+ Treg) that express Foxp3 play key roles in the maintenance of self-tolerance and suppress the activation of conventional T cells and dendritic cells (Non-Patent Document 3). Moreover, several reports suggest the essential role of CD25+ Treg, including CD4+CD25+CXCR5+ follicular Treg (TFR) (Non-Patent Document 2) and CD4+CD25+CD69− Treg (Non-Patent Document 4), in the regulation of humoral immunity. These observations clearly indicate that CD25+ Treg systemically suppress autoimmunity; however, the pathology of diseases induced by the absence of functional CD25+ Treg is quite different from SLE (Non-Patent Documents 1 and 5) and the role of CD25+ Treg in SLE has not been clarified (Non-Patent Document 6). Recent advances in the studies of CD8+ Treg in mice have underscored the importance of Qa-1-restricted CD8+ Treg for the maintenance of B cell tolerance. Mice with functional impairment in CD8+ Treg exhibit a lupus-like disease pathology with a significant increase in TFH (Non-Patent Document 7). The development of systemic autoimmune reactions in B6.Yaa mutant mice is associated with a pronounced defect in CD8+ Treg activity (Non-Patent Document 8). Nevertheless, the actual contribution of CD8+ Treg to the regulation of human autoimmune reactions remains unclear.
Early growth response gene 2 (Egr2), a zinc-finger transcription factor, plays a critical role in hindbrain development and myelination of the peripheral nervous system (Non-Patent Document 9). In T cells, Egr2 is important for the maintenance of T cell anergy by negatively regulating T cell activation (Non-Patent Document 10). The involvement of Egr2 in the control of systemic autoimmune reactions was first suggested by the observation that lymphocyte-specific Egr2-deficient mice develop a lupus-like disease with no impact on the development of Foxp3-expressing CD25+ Treg (Non-Patent Document 11). Moreover, mice deficient for both Egr2 and Egr3 in B and T cells present a lethal and early-onset systemic autoimmune disease, suggesting a synergistic role for Egr2 and Egr3 in controlling B cell tolerance (Non-Patent Document 12). The present inventors and their collaborators have shown that polymorphisms in EGR2 influence SLE susceptibility in humans (Non-Patent Document 13). The present inventors have previously identified the existence of Egr2-controlled CD4+CD25−LAG3+ Treg (LAG3+ Treg) (Non-Patent Document 14). LAG3 is a CD4-related molecule that binds to MHC class II, and the binding induces ITAM-mediated inhibitory signaling in dendritic cells (Non-Patent Document 15). Approximately 2% of the CD4+CD25− T cell population in the spleen expresses LAG3. These LAG3+ Treg produce high levels of interleukin (IL)-10 and are suppressive in a murine model of colitis in an IL-10-dependent manner. Unlike CD25+ Treg, high affinity interactions with selecting peptide/MHC ligands expressed in the thymus do not induce the development of LAG3+ Treg. Recently, Gagliani et al. reported that concomitant expression of LAG3 and CD49b is specific for IL-10-producing type 1 T regulatory (Tr1) cells (Non-Patent Document 16), suggesting that LAG3 is one of the markers of IL-10-producing Foxp3-independent CD4+ Treg.
The relationship between Egr2 and systemic autoimmune reactions mediated by autoantibodies has suggested the involvement of Egr2-expressing LAG3+ Treg in B cell response regulation. However, the mechanism of humoral immunity regulation by LAG3+ Treg has not been elucidated, and in particular, the factors that mediate suppression of B cell activation by LAG3+ Treg have not been identified.
An objective of the present invention is to elucidate the mechanism of action by LAG3+ Treg, and also to provide novel suppressors of B cell activation and therapeutic agents for autoimmune diseases based on this finding.
As a result of dedicated research, the present inventors demonstrated that transforming growth factor-β3 (TGF-β3) produced by LAG3+ Treg is involved in the regulation of B-cell response. In addition, the present inventors confirmed that introduction of TGF-β3 significantly improves the pathology of MRL/lpr mice which are model mice for SLE pathology. Furthermore, the present inventors discovered that suppression of B cell activation through TGF-β3 may also take place in human LAG3+ Treg through the same mechanism as in mouse LAG3+ Treg.
The present invention is based on these novel findings, and provides suppressors and therapeutic agents that use TGF-β3.
More specifically, the present invention relates to the following:
[1] a suppressor of B cell activation, which comprises TGF-β3;
[2] the suppressor of [1], wherein the B cell is an autoreactive B cell;
[3] the suppressor of [1] or [2], wherein the TGF-β3 suppresses antibody production by B cells;
[4] a therapeutic agent for an autoimmune disease, which comprises the suppressor of any one of [1] to [3];
[5] a therapeutic agent for an autoimmune disease, which comprises a molecule in which TGF-β3 is linked with an antibody or an antibody fragment;
[6] the therapeutic agent of [5], wherein the antibody or the antibody fragment comprises a variable region that recognizes a B cell;
[7] the therapeutic agent of [6], wherein the variable region recognizes the B cell using any one or more of CD19, CD20, CD40, CD22, IL21R, BAFF-R, BCMA, TACI, CD27, and CD138 as a marker;
[8] a therapeutic agent for an autoimmune disease, which comprises a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell;
[9] the therapeutic agent of any one of [4] to [8], wherein the autoimmune disease is any one of systemic lupus erythematosus, pemphigus, multiple sclerosis, neuromyelitis optica, ANCA-associated vasculitis, rheumatoid arthritis, organ transplant rejection, Sjogren's syndrome, juvenile dermatomyositis, myasthenia gravis, or autoimmune thyroid disease including Graves' disease and Hashimoto's thyroiditis; and
[10] a medical kit comprising the therapeutic agent of any one of [4] to [8].
The present invention also relates to the following.
[11] a method for suppressing B cell activation, wherein the method comprises administering TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell;
[12] a method for treating an autoimmune disease, wherein the method comprises administering TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell;
[13] TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell for use in suppressing B cell activation;
[14] TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell for use in treating an autoimmune disease;
[15] use of TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell in the manufacture of a suppressor of B cell activation; and
[16] use of TGF-β3; a molecule in which TGF-β3 is linked with an antibody or an antibody fragment; or a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes a B cell in the manufacture of an agent for treating an autoimmune disease.
The present invention provides suppressors of B cell activation comprising TGF-β3. B cells are preferably autoreactive B cells, and examples of B cell activation suppression include suppression of antibody production by B cells. The suppressors can be used as therapeutic agents for autoimmune diseases.
TGF-β3 includes those having an amino acid sequence shown in SEQ ID NOs: 1 to 6; those having an amino acid sequence produced by partial alteration or modification of these amino acid sequences and having the same B cell activation suppressing activity, and also the latent and mature forms. Examples of the autoimmune diseases include systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis, neuromyelitis optica (NMO), ANCA-associated vasculitis, rheumatoid arthritis, organ transplant rejection, Sjogren's syndrome, juvenile dermatomyositis, myasthenia gravis, and autoimmune thyroid disease including Graves' disease and Hashimoto's thyroiditis.
From another viewpoint, the present invention provides therapeutic agents for autoimmune diseases, which comprise a molecule formed by linking TGF-β3 with an antibody or an antibody fragment. An antibody fragment indicates a fragment produced by separating antibody components such as the variable region or the Fc region.
The antibody or antibody fragment may have a configuration in which a variable region that recognizes B cells is contained. B cells can be recognized using, for example, any one or more of CD19, CD20, CD40, CD22, IL21R, BAFF-R, BCMA, TACI, CD27, and CD138 as markers.
From another viewpoint, the present invention provides therapeutic agents for autoimmune diseases, which comprise a multispecific antibody comprising a first variable region that recognizes TGF-β3 and a second variable region that recognizes B cells.
From another viewpoint, the present invention provides therapeutic agents for autoimmune diseases, which comprise a molecule formed by linking TGF-β3 with PEG, a polysaccharide, or an artificial polypeptide, or a molecule formed by glycosylation of TGF-β3.
From another viewpoint, the present invention provides medical kits comprising the aforementioned therapeutic agents.
All prior art documents cited in this description are incorporated herein by reference.
Herein below, the present invention will be specifically described with reference to the Examples, but it is not to be construed as being limited thereto. The accession number for the microarray data presented in the Examples is the number of E-MEXP-1343 [the ArrayExpress database].
C57BL/6 (B6), C57BL/6-Faslpr/lpr (B6/lpr), C57BL/6-FasLgld/gld (B6/gld), MRL-Faslpr/lpr (MRL/lpr), and MRL-Fas+/+ (MRL/+) mice were purchased from Japan SLC. B6 recombinase-activating gene (Rag)-1-deficient (RaglKO) mice, floxed-Prdm1 (Prdm1fl/fl) mice, Il10-deficient (IL-10KO) mice, T cell receptor (TCR) transgenic OT-II mice (specific for the chicken ovalbumin peptide (amino acid residues 323-339) in the context of MHC class II I-Ab) and TEa mice (specific for the Eα peptide (amino acid residues 52-68) from the MHC class II I-Eα molecule in the context of I-Ab) were purchased from Jackson Laboratories. Floxed-Stat3 (Stat3fl/fl) mice was purchased from Oriental Bio Service (Japan). RaglKO mice were housed in microisolator cages with sterile filtered air. B6-Pdcd1-deficient (PD-1KO) mice (Non-Patent Document 47) were purchased from RIKEN BRC (Japan). Floxed Egr2 (Egr2fl/fl) mice were provided by Patrick Charnay (INSERM, France) (Non-Patent Document 48). Egr2 conditional knockout (CKO) mice (Egr2fl/fl CD4-Cre+), Prdm1 CKO mice (Prdm1fl/fl CD4-Cre+), and STAT3 CKO (Stat3fl/fl CD4-Cre+) were generated by crossing Egr2fl/fl mice, Prdm1fl/fl mice, or Stat3fl/fl mice with CD4-Cre transgenic mice on a B6 background, respectively. CD4-Cre transgenic mice (line 4196) and Stat1-deficient (STAT1KO) mice were purchased from Taconic. Age- and sex-matched mice ≥7 weeks of age were used for all experiments. All animal experiments were approved by the ethics committee of the University of Tokyo Institutional Animal Care and Use Committee.
The following reagents were purchased from BD Pharmingen: purified monoclonal antibody (mAb) for CD3ε (145-2C11), FasL blocking (MFL3), anti-CD40 (3/23), Fc block (anti-CD16/CD32), FITC anti-CD45RB (16A), FITC anti-Fas (Jo2), PE anti-CD45RB (16A), APC-Cy7 anti-CD45RB (16A), PE anti-LAG3 (C9B7W), APC anti-LAG-3 (C9B7W), FITC anti-IgG1 (A85-1), APC anti-IgG1 (A85-1), FITC anti-GL7 (Ly-77), FITC anti-CD25 (PC61), PE anti-CD25 (PC61), APC anti-CD25 (PC61), APC-Cy7 anti-CD25 (PC61), APC anti-CD4 (L3T4), APC-Cy7 anti-CD4 (L3T4), PE anti-CXCR5 (2G8), APC-Cy7 anti-B220 (RA3-6B2), PE anti-PD-1 (J43), biotinylated mAb for CD8a (53-6.7), CD19 (1D3), CD11c (HL3), CD45RB (16A), CD25 (7D4), and CXCR5 (2G8), streptavidin (SA)-FITC antibody (Ab), SA-APC, and SA-APC-Cy7. Alexa Fluor 488 anti-LAG3 mAb (C9B7W) and FITC anti-PD-L1 mAb (MIH6) were purchased from AbD Serotec. Qdot605 anti-CD4 mAb (RM4-5) and SA-Qdot605 were purchased from Invitrogen. PE anti-PD-L1 mAb (MIH5), PE anti-Egr2 mAb (erongr2), PE anti-PD-L1 mAb (10F. 9G2), and APC anti-B220 mAb (RA3-6B2) were purchased from eBioscience. NP(13)-OVA, and NP(9)-BSA were purchased from Biosearch Technologies. SA-conjugated microbeads were purchased from Miltenyi Biotec. FITC anti-mouse IgG Ab was purchased from Sigma. Anti-PD-L1 blocking mAb (10F.9G2) was purchased from Biolegend. Alexa 488 Fluor anti-GFP mAb was purchased from Medical & Biological Laboratories. Recombinant TGF-β1 (rTGF-β1) and rTGF-β3 were purchased from Miltenyi Biotec, and rTGF-β2, anti-TGF-β3 blocking polyclonal Ab (MAB234), and rIL-27 were purchased from R&D Systems.
For studies using human-derived cells, the following anti-human mAbs were used: V450 anti-hCD4 (RPA-T4), V500 anti-hCD4 (RPA-T4) (both from BD Biosciences), PerCP-Cy5.5 anti-human CD3 (UCHT1), Brilliant Violet 421 anti-hCD25 (BC96), APC anti-hCD19 (HIB 19), PerCP-Cy5.5 anti-hCD4 (OKT4), Alexa Fluor 647 anti-hCD197 (G043H7), APC-Cy7 anti-human CD45RA (HI100) (all from BioLegend), Alexa Fluor 488 anti-hCD25 (BC96), and PE-Cy7 anti-hCD127 (eBioRDR5) (all from eBioscience). PE anti-hLAG3 polyclonal Ab was purchased from R&D Systems.
T cells and B cells were cultured in an RPMI-1640 medium supplemented with 10% FBS, 100 μg/ml L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-mercaptoethanol (all purchased from Sigma).
The bacterial artificial chromosome (BAC) clone RP23-88D4, which contained the entire genomic Egr2 locus, was obtained from BAC Libraries (Invitrogen). This clone was modified for the insertion of an enhanced green fluorescent protein gene (eGFP) with an SV40 polyA sequence at the initiation codon in Egr2 exon 1 using the Red/ET recombination system. The Egr2-eGFP construct linearized with PI-SceI was injected into the pronuclei of fertilized zygotes from B6 mice and transferred to pseudopregnant females. Offspring were screened for genomic integration by PCR of tail DNA using the following:
(PCR product size: 2.1 kb). Mice were generated by breeding F1 heterozygous transgenic males with wild-type (WT) females.
Mouse spleens were cut into pieces and treated with collagenase type IV (Sigma-Aldrich). Red blood cells were lysed by hypotonic shock in an ammonium chloride with potassium (ACK) lysis buffer, followed by immediate isotonic restoration. Surface staining was performed in ice-cold PBS with 2% FCS in the presence of an FcR blocking antibody (anti-mouse CD16/CD32 mAb). To obtain highly purified CD4+ T cells, single-cell suspensions were first purified by negative selection with magnetic-activated cell sorting (MACS; Miltenyi Biotec) using anti-B220 mAb, anti-CD19 mAb, anti-CD11c mAb, and anti-CD8a mAb. To obtain highly purified CD4+CD25−CD45RBlowLAG3+ T cells, CD45RBhigh cells were subsequently depleted with anti-CD45RB mAb. After FcR blocking, the prepared cells were stained with mAbs specific for CD4, CD25, CD45RB, and LAG3 in order to isolate CD4+CD25−CD45RBlowLAG3+ T cells (LAG3+ Treg), CD4+CD25+ T cells (CD25+ Treg), CD4+CD25−LAG3− helper T cells (Th cells) or CD4+CD25−CD62LhiCD44low (naïve T). Cells for intracellular anti-Egr2 staining were stained using the Foxp3 Staining Buffer Set (eBioscience) according to the manufacturer's protocol. The purities of MACS-sorted, and FACS (FACSVantage SE (Becton-Dickinson) or MoFlo XDP (Beckman Coulter))-sorted cells were >90% and >99%, respectively.
An NP-OVA alum solution was prepared by mixing NP(13)-OVA (Biosearch Technologies) in PBS solution with alum (Pierce) at a 1:1 ratio for 30 min at 4° C. The immunization with NP-OVA/alum was performed by i.p. injection.
Adoptive Transfer of LAG3+ Treg from WT Mice into Egr2CKO Mice
FACS-purified 2×105 LAG3+ Treg from B6 mice were injected i.v. into 10-week-old Egr2CKO mice pre-immunized with or without 100 μg NP-OVA/alum 1 day prior to the cell transfer. The differentiation of TFH and GCB in the spleen was analyzed by FACS 7 days after the cell transfer. The serum level of the anti-BSA-NP antibody was analyzed by ELISA 7 days after the immunization, as described above.
Splenic B cells were purified by negative selection with MACS using a B cell isolation kit (Miltenyi Biotec) according to the manufacturer's protocol. The purity of MACS-sorted B cells was >95% positive for B220 staining. B cells were labeled with 5 μM 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE; Dojindo) at 37° C. for 10 min, and then stimulated with 10 μg/ml anti-IgM F(ab)′2 (Jackson ImmunoResearch Laboratories) for 72 hours with or without rTGF-β1, 2, or 3 for B cell proliferation assays. Cells were stained with anti-B220 mAb, 7-Amino-Actinomycin D (7-AAD) (Biolegend) and PE anti-CD40 mAb. The percentages of viable 7-AAD-negative CFSE-diluted B220+CD40+ B cells and dead 7-AAD-positive B220+ cells were assessed by FACS.
The wells of 96-well flat-bottomed plates were coated with 10 μg/ml of anti-CD3 mAb in 100 μl/well of PBS and incubated overnight at 4° C. The wells were washed, and MACS-purified B cells and each FACS-purified T cell subset (LAG3+ Treg, CD25+ Treg, or CD4+CD25−CD44loCD62Lhi naïve T cells) or IL-27-treated CD4+ T cells described below were added into the coated wells at a density of 1×105 cells/well in an RPMI medium containing 10 μg/ml of anti-CD40 mAb (3/23)+10 μg/ml rIL-4 (Cell Signaling Technology) supplemented with or without rTGF-β3 (1 ng/ml). B cells undergoing apoptosis on day 3 and total IgG production in the culture supernatants on day 7 were determined using the Annexin V Apoptosis Detection Kit (BD Pharmingen) and a mouse IgG ELISA Quantitation Set (Bethyl Laboratories), respectively, according to the manufacturer's protocol.
2×105 of MACS-purified B cells from B6 or PD-1KO mice and 2×105 of FACS-purified Th cells from OT-II or PD-1KO OT-II mice were injected i.v. into RaglKO mice in combination with or without 1×105 of FACS-purified LAG3+ Treg from B6, Egr2CKO, B6/lpr, B6/gld, or IL-10KO mice. Control mice received PBS. Mice were subsequently immunized with 100 μg of NP-OVA/alum 24 hours after the cell transfer. Mice were re-immunized with 50 μg of NP-OVA/alum 14 days after the first immunization. Where indicated, on the day after the cell transfer, mice were injected i.v. with an anti-FasL blocking antibody (200 μg/mouse) or an anti-TGF-β3 blocking antibody (100 μg/mouse) at weekly intervals, or an anti-PD-L1 blocking antibody (200 μg/mouse) every 3 days. The serum level of the anti-NP antibody was analyzed by ELISA, and splenocytes were analyzed by FACS 7 days after the re-immunization.
The anti-NP IgG antibody levels were quantified by ELISA using NP(9)-BSA (Biosearch Technologies) as the capture antigen in the in vitro or in vivo antibody production assay. ELISA plates were prepared using the Immuno-Tek ELISA construction system (Zepto Metrix) according to the manufacturer's protocol. Following incubation with the sample serum or media, the plates were developed with an HRP-conjugated goat anti-mouse IgG1 and a TMB substrate. Serially diluted pooled sera from NP(13)-OVA immunized B6 mice were included as control on each plate. The concentration of the anti-NP IgG1 antibody was estimated by comparison with a standard curve constructed from the pooled sera.
2×105 of FACS-purified Th cells from OT-II mice were injected i.v. into TEa mice in combination with or without 1×105 of FACS-purified LAG3+ Treg from B6 mice. Control mice received PBS. Mice were subsequently immunized with 100 μg of NP-OVA/alum 24 hours after the cell transfer. The serum level of the anti-BSA-NP antibody was analyzed by ELISA 14 days after the immunization, as described above.
Eight-week-old MRL/lpr mice were randomly assigned to specific treatment groups. Ten-week-old MRL/lpr mice in the treatment group were injected i.v. with LAG3+ Treg, LAG3 T cells, CD25+ Treg, or naïve T cells (1×105 cells each) obtained from MRL/+ mice. The three-time injection group (MRL/+LAG3+ Treg ×3, MRL/+CD25+ Treg ×3, and MRL/lpr LAG3+ Treg ×3) was adoptively transferred i.v. with 1×105 LAG3+ Treg at weekly intervals (10, 11, and 12 or 13, 14, and 15 weeks of age, respectively; the mice were 10 weeks of age at the time of the first injection). Each T cell subset was first enriched by MACS and then sorted by FACS (based on the expression of CD4, CD25, CD45RB, and LAG3) as described above. Mice in the control group received PBS. Where indicated, on the day after the first cell transfer, mice were injected i.v. with an anti-TGF-β3 blocking antibody (100 μg/mouse) at weekly intervals. Mice were sacrificed at 18 weeks of age to examine pathological alterations. The anti-ds DNA antibody was measured using a mouse anti-ds DNA ELISA Kit (Shibayagi) at 13 and 18 weeks of age, according to the manufacturer's protocol.
Proteins in the urine were assessed semiquantitatively using dip sticks (Albustix, Bayer) at weekly intervals (0=none; 1=30 to 100 mg/dl; 2=100 to 300 mg/dl; 3=300 to 1,000 mg/dl; 4≥1,000 mg/dl).
MRL/lpr mice were sacrificed at 18 weeks of age. Renal pathology was graded by standard methods for glomerular inflammation, proliferation, crescent formation, and necrosis as described in Non-Patent Document 49. The glomeruli were evaluated by examining at least 80 glomeruli per section by an examiner blind to the experimental conditions. Interstitial and tubular changes were also noted. Scores from 0 to 4 (where 0 represents “no damage” and 4 represents “severe”) were assigned for each of these features.
B6 and OT-II mice were immunized with 100 μg of NP-OVA/alum. Mice were re-immunized with 100 μg NP-OVA/alum three weeks after the first immunization. 2×105 of MACS-purified B cells from pre-immunized B6 mice and 1×105 of FACS-purified CD4+CD25− LAG3− helper T cells (Th cells) from pre-immunized OT-II mice were seeded in round-bottom 96-well plates 7 days after the re-immunization in combination with or without 1×105 of FACS-purified LAG3+ Treg from non-immunized OT-II mice in the presence or absence of 10 μg/ml of an anti-PD-L1 blocking mAb (10F.9G2) or 10 μg/ml of an anti-FasL blocking mAb (MFL3). The culture supernatants were harvested at 3 weeks, and the anti-NP antibody level was analyzed by ELISA, as described above.
RNA Isolation, cDNA Synthesis, and Quantitative Real-Time PCR
Total T cell RNA was prepared using an RNeasy Micro Kit (Qiagen). RNA was reverse-transcribed into cDNA, and quantitative real-time PCR analysis was performed as described in Non-Patent Document 14. Relative RNA abundance was determined based on the abundance of control mouse β-actin or human GAPDH.
Total RNA of CD4+CD25+, CD4+CD25−CD45RBlowLAG3+, and CD4+CD25− CD45RBhighLAG3− FACS-purified T cells from B6 mice were harvested and then prepared for Affymetrix microarray analysis as described in Non-Patent Document 14. Microarray data were analyzed using Bioconductor (version 1.9) and statistical software R and GeneSpring GX version 7.3.1 (Silicon Genetics). All microarray data have been deposited in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under Accession No. E-MEXP-1343, which is identical to a previous study from the present inventors' laboratory (Non-Patent Document 14).
Each T cell subset was plated into anti-CD3 mAb or anti-CD3 mb/anti-CD28 mAb-coated wells at 3×105 cells per well in a serum-free X-Vivo-20 medium (Lonza) for the determination of TGF-β1 and 2, or the RPMI medium described above for TGF-β3. All cultures were incubated at 37° C. for 72 hours, and the supernatants were collected and stored at −80° C. TGF-β1, 2, and 3 levels in supernatants were determined by the TGF-β1 Emax ImmunoAssay System (Promega), TGF-β2 Quantikine ELISA Kit (R&D Systems), and TGF-β3 ELISA Kit (Mybiosource), respectively, according to the manufacturer's protocol. TGF-β3 levels in the RPMI medium supplemented with 10% FBS were lower than the minimum detectable level of the TGF-β3 ELISA Kit.
MACS-purified B cells from B6 mice were pretreated with 0.75 μM CpG-ODN (ENZO Life Science) for 72 hours supplemented with or without rTGF-β3 (20 ng/ml) during the last 16 hours, and subsequently stimulated with 10 μg/ml of anti-CD40 mAb, 10 μg/ml of rIL-4, or 10 μg/ml of anti-IgM F(ab)′2 in the RPMI medium. Following the stimulation, cells were treated in Lysis Buffer (50 mM Tris-HCl, 0.15 M NaCl, 1% Triton X-100, 1 mM EDTA), denatured in 2×Laemmli Buffer (BioRad) at 95° C. for 5 min, and separated by electrophoresis on Mini-PROTEAN TGX precast gels (BioRad). The total protein concentration in the cell lysates was determined using a BCA Protein Assay kit (Pierce). Gels after electrophoresis were blotted onto polyvinylidene fluoride (PVDF) membranes and blocked with 5% BSA, then reacted with antibodies against phospho- or total STAT6, NF-κB p65, or Syk (all purchased from Cell Signaling Technology), and further probed with secondary anti-rabbit-IgG-HRP (Invitrogen) antibodies. Membranes were developed with the ECL Prime substrate (GE Healthcare).
MACS sorted CD4+ T cells described above were further purified as CD4+CD25−CD62L+CD44− naïve T cells by FACS, and cells were seeded at a density of 3×105 cells per 100 μl of RPMI culture medium described above in 96-well plates coated with 2 μg/ml anti-CD3 mAb and 2 μg/ml anti-CD28 mAb. Cytokines for effector cell differentiation were as follows: Th0, anti-IFN-γ (10 μg/ml; XMG1.2), and anti-IL-4 (10 μg/ml; 11B11); Th0, anti-IFN-γ (10 μg/ml; XMG1.2 (BD Pharmingen)), and anti-IL-4 (10 μg/ml; 11B11 (BD Pharmingen)); Th1, IL-12 (10 ng/ml (R&D Systems)), IL-2 (50 μg/ml (R&D Systems)), and anti-IL-4 (10 μg/ml; 11B11); Th17, TGF-β1 (1 ng/ml), IL-6 (50 ng/ml (BioLegend)), IL-23 (50 ng/ml (R&D Systems)), anti-IFN-γ (10 μg/ml; XMG1.2), and anti-IL-4 (10 μg/ml; 11B11); induced Treg, TGF-β1 (5 ng/ml) and anti-IL-4 (10 μg/ml; 11B11). The culture supernatants were harvested on day 5, and TGF-β3 levels were analyzed by ELISA as described above.
In Vitro CD4+Erg2+LAG3+ Treg Differentiation by IL-27
In vitro stimulation of MACS purified naïve CD4+ T cells using the CD4+CD62L+ T Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer's protocol was performed in 24- or 96-well plates coated with 2 μg/ml of anti-CD3 mAb and 1 μg/ml of anti-CD28 mAb in the RPMI culture medium described above supplemented with 25 ng/ml IL-27 for 5 days. IL-27-treated naïve T cells were subsequently sorted by flow cytometry for CD4 expression and used for each assay. For determination of the TGF-β3 level in the culture supernatants by ELISA, IL-27-treated T cells were stimulated with PMA (50 ng/ml; Sigma) and ionomycin (1 μg/ml; Sigma) for the final 4 hours.
A full-length fragment of murine TGF-β3 was isolated from an OmicsLink™ Expression-Ready ORF-cloning vector (GeneCopoeia) containing a Tgfb3 cDNA (NM_009368). The Tgfb3 cDNA was subcloned using EcoRI sites into the pCAGGS vector (Non-Patent Document 50), which has the CAG (cytomegalovirus immediately-early enhancer/chicken β-actin hybrid) promoter, and was designated as pCAGGs-Tgfb3. Recombinant plasmids were then transformed into competent cells of Escherichia coli JM109 and purified on plasmid purification columns using EndFree Plasmid Giga Kit (Qiagen) according to the manufacturer's protocol. The purified plasmid DNA was diluted to 1 μg/μl with sterile PBS (pH 7.4) immediately before use.
MRL/lpr mice were injected i.v. with 100 μg of plasmid DNA (pCAGGs-Tgfb3 or control pCAGGS) in sterile PBS (pH 7.4) twice at an interval of 4 weeks. Proteinuria was assessed semiquantitatively at weekly intervals, and renal pathology was evaluated 6 weeks after the final administration as described above.
All human samples were obtained under informed consent. The protocol for the human research project has been approved by the Ethics Committee of the University of Tokyo. PBMCs from healthy and SLE patients were isolated by Ficoll-Paque (Amersham Pharmacia Biotech) gradient. After the cells were washed, they were stained with the indicated mAbs for 20 minutes at 4° C. To prevent non-specific binding of mAbs, Human Fc Receptor Binding Inhibitor (eBioscience) was added before staining with labelled mAb. Dead cells were excluded by 7-AAD. The fluorescence-positive cells were analyzed by a Moflo XDP cell sorter. The five distinct subpopulations are as follows: (naïve T) CD4+CD25−CD45RA+CCR7+ cells; (CD25+ Treg) CD4+CD25+CD127dimCD45RA− cells; (LAG3+ Treg) CD4+CD25−CD45RA−LAG3+ cells; (Tfh) CD3+CD19−CD4+CD25−LAG3−CXCR5+CD45RA− cells; (B cells) CD3−CD19+ cells.
Total RNA isolated from human naïve T and CD25+ Treg, and LAG3+ Treg stimulated with plate-bound 5 μg/ml anti-CD3 mAb for 72 hours were analyzed for the mRNA expression of EGR2, IL10, IFNG, and FOXP3, as described above. The TGFB3 mRNA expression was determined using unstimulated cells from each T cell subset.
For cytokines analysis, human naïve T, CD25+ Treg, and LAG3+ Treg were plated into 5 μg/ml anti-CD3 mAb/anti-CD28 mAb-coated 96-well flat-bottomed plates at 2×104 cells per well in an RPMI-1640 medium supplemented with 10% FBS, 100 μg/ml L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-mercaptoethanol. The culture supernatants were harvested on day 3, and the level of IL-10 in the culture supernatants was analyzed by ELISA using OptEIA Human IL-10 ELISA Kit II (BD Biosciences) according to the manufacturer's protocol.
The RPMI-1640 medium described above was used for co-culturing. 1×105 of FACS-purified human B cells and 5×104 of FACS-purified human TFH cells were seeded in round-bottom 96-well plates with or without 1×105 of FACS-purified human CD25+ Treg or LAG3+ Treg in the presence of 2 μg/ml of recombinant Staphylococcal enterotoxin B (Toxin Technology). The culture supernatants were harvested on day 12, and the levels of total IgG were analyzed by ELISA using Human IgG Quantitation Set kits (Bethyl Laboratories), according to the manufacturer's protocol.
Statistical significance, normal distribution, and F test between groups were analyzed using GraphPad Prism version 5.03 (GraphPad Software, Inc.). Quantitative histology and proteinuria progression were analyzed with the Mann-Whitney U-test. All other statistical differences were determined using the two-tailed Student's t-test. If the variance was unequal, Welch's correction was applied to Student's t-test. Differences were considered statistically significant at P<0.05 for all tests. All data in the figures are expressed as mean±s.d. Sample size was estimated based on the numbers typically used in previous studies. No statistical method was used to predetermine sample size. No samples or animals were excluded from the analyses. Randomization of animals was not performed except for adoptive transfer studies in MRL/lpr mice. Animal studies were not performed in a blinded fashion except for histological analyses.
To clarify the role of Egr2 in T cells, the present inventors generated T cell-specific Egr2 conditional knockout (CKO) mice (Egr2fl/fl CD4-Cre+). Egr2 CKO mice showed significant increases in the proportion of CD4+CD25−CXCR5+PD-1+ TFH and B220+GL-7+Fas+ follicular B cells (GCB) (
The present inventors investigated whether LAG3+ Treg were able to inhibit disease progression in lupus-prone MRL-Faslpr/lpr (MRL/lpr) mice with a Fas mutation (Non-Patent Document 17). MRL/lpr mice were adoptively transferred with various T cell subsets from MRL-Fas+/+ (MRL/+) mice not having a Fas mutation. LAG3+ Treg but not CD25+ Treg significantly delayed proteinuria progression (
The therapeutic effect of LAG3+ Treg from MRL/+ in Fas-mutated MRL/lpr mice suggested that Fas contributes to the suppressive ability of LAG3+ Treg. The present inventors examined the correlation between suppressive ability on humoral immunity of LAG3+ Treg and Fas expression in B6 background mice. Adding anti-FasL blocking antibody abrogated LAG3+ Treg-mediated antibody suppression both in vitro (
We next examined whether B cell suppression by LAG3+ Treg is mediated by IL-10 or TGF-β family members. As described above, LAG3 is considered to be one of the specific cell-surface markers for Tr1 cells (Non-Patent Document 16). The present inventors previously reported that LAG3+ Treg produce large amounts of IL-10 (Non-Patent Document 14), and Egr2 mediates IL-27-induced IL-10 production in CD4+ T cells through B lymphocyte induced maturation protein-1 (Blimp-1) (coded by Prdm1 gene) (Non-Patent Document 19). As expected, IL-10 expression levels were significantly reduced in LAG3+ Treg from T cell specific Prdm1CKO mice (Prdm1fl/fl CD4-Cre+) compared to WT mice (
Administration of a TGF-β3 blocking antibody cancelled the LAG3+ Treg co-transfer-mediated suppression of antibody production and the development of TFH and GCB in Rag1KO mice transferred with WT B cells and WT OT-II Th cells and immunized twice with OVA-NP (
Variants of the programmed cell death-1 (PD-1) gene have been associated with SLE susceptibility (Non-Patent Document 1). PD-1 provides negative co-stimulatory signals to both T cells and B cells (Non-Patent Documents 25 and 26) and PD-1-deficient (PD-1KO) mice develop a lupus-like disease (Non-Patent Document 27). Furthermore, PD-1 and LAG3 synergistically regulate autoimmunity and tumor immunity (Non-Patent Documents 28 and 29). To examine the potential cooperation between rTGF-β3 and PD-1, the present inventors added TGF-β3 to anti-IgM antibody-stimulated B cells from B6, PD-1KO, Fas-deficient B6/lpr, and FasL-deficient B6/gld mice. PD-1KO mice-derived B cells, but not B6/lpr mice-derived or B6/gld mice-derived B cells, were resistant to the TGF-β3-induced inhibition of cell division (
IL-27-Mediated Induction of TGF-β3-Producing Egr2+ T Cells with B Cell Response-Suppressing Function
IL-27 is a member of the IL-12/IL-23 heterodimeric family of cytokines produced by antigen presenting cells (APCs). IL-27 has been identified as a differentiation factor for IL-10 producing Tr1 cells (Non-Patent Document 32). The present inventors have previously reported that IL-27 induces Egr2 expression in CD4+ T cells and Egr2 is required for the Blimp-1-mediated IL-10 production (Non-Patent Document 19). IL-27 treatment induced not only Egr2 and LAG3 (
Mechanism of Suppression of Antibody Production by Human LAG3+ Treg, and Correlation Between Human LAG3+ Treg and Systemic Lupus Erythematosus
The present inventors identified CD4+CD25-CD45RA−LAG3+ T cells in CD4+ T cells from peripheral blood mononuclear cells (PBMCs) of healthy donors (
It is understood that generally TGF-β3 and TGF-β1 show similar biological activities, at least in vitro, via common signaling molecules. However in vivo, mainly through results from knockout mice, the two have been reported to have different phenotypes, and this difference is caused by the timing and location of expression; alternatively, since TGF-β1 KO mice, which are inherently lethal, that have a TGF-β3 knock-in are rescued but also show different phenotypes, there has also been suggested the possibility that the two show different biological activities in vivo (Non-Patent Document 51).
On the other hand, from reports on immune systems, TGF-β3 has been reported to induce pathogenic T cells (Th17 cells) and worsen pathological conditions in experimental autoimmune encephalomyelitis (EAE) models, a report which is opposite from the current experimental results (Non-Patent Document 52). This document shows that this action is absent in TGF-β1. Similarly, involvement of TGF-β3 in aggravation of autoimmune diseases has been reported in TRIM28 KO mice as well (Patent Document 52). These mice are short lived due to spontaneous autoimmune diseases and show worsened EAE, and TGF-β3 derepression is considered to be involved therein.
As such, existing reports suggested that TGF-β3 and TGF-β1 have different activities in vivo. Accordingly, to comparatively investigate the immunosuppressive actions of TGF-β3 observed this time with respect to the actions of TGF-β1, the present inventors examined the effects of expression of the two genes on SLE-like conditions by expressing genes encoding the full-length TGF-β1 and TGF-β3 in MRL/lpr mice, which are spontaneous models of SLE. Full-length TGF-β1 and TGF-β3 cloned into pCAGGS plasmids and a control pCAGGS plasmid were each administered at 100 μg to MRL/lpr mice through the caudal vein. Each plasmid was administered twice, i.e., at 11 weeks and 15 weeks of age, and subsequently, various pathological parameters were measured.
As a result, the TGF-β3 expression plasmid significantly suppressed the spleen weight (at 21 weeks of age) and the increase of proteinuria over time in comparison to the control plasmid, and these effects tended to be stronger than those of the TGF-β1 expression plasmid (
The above-mentioned results suggested that the difference in therapeutic effects of TGF-β1 and TGF-β3 in MRL/lpr mouse models may depend on the presence or absence of the ability to suppress follicular helper T cells that are important for immune responses involving antibody production. Thus, TGF-β3 may be useful in the treatment of autoimmune diseases such as SLE through suppression of follicular helper T cells, which is an action not found in TGF-β1.
The results of the present study demonstrated that LAG3+ Treg suppress the development of GCB and TFH, antibody production, and disease progression in MRL/lpr mice showing lupus-like pathologies. TGF-β3, which is produced by LAG3+ Treg in Egr2-dependent and Fas-dependent manners, plays a critical role in suppressing humoral immunity. As LAG3+ Treg also produce much higher levels of IL-10 than CD25+ Treg (Non-Patent Document 44), LAG3+ Treg are potent producers of regulatory cytokines. The pro-inflammatory role of TGF-β3 was previously demonstrated by the observation that TGF-β3 efficiently induces pathogenic Th17 cells (Non-Patent Documents 24 and 34). The results of the present inventors have revealed a previously unrecognized role for TGF-β3 in the control of autoimmunity. TGF-β1 also exerts both pro-inflammatory and anti-inflammatory effects (Non-Patent Documents 35-37). In particular, TGF-β1 induces B cell apoptosis and reduces immunoglobulin production from activated human tonsil B cells (Non-Patent Documents 38 and 39). CD25+ Treg and Th3 regulatory cells (Non-Patent Documents 40 and 41) are potent sources of TGF-β1, and CD25+ Treg have been shown to suppress B cell immunoglobulin synthesis through TGF-β1 (Non-Patent Document 42). However, the amount of TGF-β1 produced by CD4+ T cells including CD25+ Treg is relatively limited (
The present inventors identified two molecules, Fas and Egr2, which are required for TGF-β3 secretion in LAG3+ Treg. Egr2 deficiency in T cells and B cells results in a lupus-like syndrome, and Egr2 directly activates p21cip1 expression in CD44high T cells and is involved in the control of Th1 and Th17 differentiation. The fact that Egr2 blocks the function of BATF, an AP-1 inhibitor required for the differentiation of Th17 cells, indicates that Egr2 is an intrinsic regulator of effector T cells (Non-Patent Document 12). The present inventors showed here that Egr2 in T cells is important for the control of the development of TFH and GCB (
IL-27, a differentiation factor for IL-10-producing Tr1 cells (Non-Patent Document 32), induces CD4+Egr2+LAG3+ T cells (Non-Patent Document 19). However, the role of Tr1 cells in the regulation of B cells is not clear because CD46-induced Tr1 cells are more potent at enhancing immunoglobulin production compared with conventional T cells (Non-Patent Document 44). In LAG3+ Treg, IL-10 did not directly contribute to the control of B cell response (
Generation of novel functional molecules using TGF-β3 was investigated by the present inventors based on the findings on suppression of B cell activation by TGF-β3. A conceivable configuration of the functional molecule is, for example, one in which TGF-β3 is linked with an antibody Fc region through amino acids and the antibody further contains a variable region that recognizes B cells. TGF-β3 can be linked with the antibody or antibody fragment through a linkage using the third TB domain (TGFbeta binding domain) of TBP (latent TGFbeta-binding protein)-1, 3, or 4; a linkage using an enzyme; or a linkage using a chemical modification reaction.
Other means include configuration of a multispecific antibody where one variable region recognizes TGF-β3 and the other variable region recognizes B cells. Another configuration is that of a fusion protein in which TGF-β3 is linked with an antibody Fc fragment, and TGF-β3 is further linked with a variable region fragment that recognizes B cells. The B cells are desirably autoreactive B cells, and B cell recognition by the variable region may be accomplished by B-cell surface markers such as CD19, CD20, CD40, CD22, IL21R, BAFF-R, BCMA, TACI, CD27, and CD138.
To provide biologically active proteins such as TGF-β3 as therapeutic agents, one may consider working the proteins stably in human plasma. As an embodiment for allowing stable action in plasma, the proteins may be linked with a protein that has long half-life in plasma such as an antibody or serum albumin. It may also be chemically linked to polyethylene glycol (PEG) or polysaccharides, or modified by glycosylation. There are also recent reports of techniques of mimicking PEG by linking a long artificial polypeptide sequence (Non-Patent Document 53).
These functional molecules stably transport TGF-β3 to B cells and effectively suppress the targeted B cell activity, and can also be applied as therapeutic agents for autoimmune diseases. Regarding autoimmune diseases, in addition to SLE to which TGF-β3 was confirmed to have improving effects, similar improving effects are expected for diseases that involve IgG production or TFH increase, such as, pemphigus, multiple sclerosis, neuromyelitis optica (NMO), ANCA-associated vasculitis, rheumatoid arthritis, organ transplant rejection, Sjogren's syndrome, juvenile dermatomyositis, polymositis/dermatomyositis, systemic sclerosis, myasthenia gravis, and autoimmune thyroid disease including Graves' disease or Hashimoto's thyroiditis.
The mouse TGFβ3 gene was prepared by using positions 24 to 410 of an amino acid sequence registered on database (Uniprot No. P17125); and for expression as latent TGFβ3, a mouse Ig kappa chain signal sequence was added to the N-terminal side, and to facilitate simple purification, a FLAG tag was fused immediately after the signal sequence. Furthermore, to improve the expression level of latent TGFβ3, Cys at position 25 in the database-registered amino acid sequence (Uniprot No. P17125) was substituted with Ser according to the information described in the publication, Molecular Therapy (2010) 18:12, 2104-2111. The genetic sequence inserted in the OmicsLink™ Expression-Ready ORF cloning vector (GeneCopoeia) was used as the wild-type TGFβ3 gene. The amino acid sequence of latent TGFβ3, excluding the signal sequence, is shown in SEQ ID NO: 11.
The TGFβ3-modified antibody molecule has a molecular shape that possesses a mouse CD19-recognizing antibody on one arm, and was prepared by attaching to its C terminus a TB3 domain (the third TB domain (TGFbeta binding domain) of TBP (latent TGFbeta-binding protein)-1, 3, and 4) for linking TGFβ3. For comparison, antibodies that do not have the TB3 domain for linking TGFβ3 were also prepared. These modified antibody molecules have a structure in which one Fab of an anti-CD19 antibody is linked to an Fc.
The antibody variable region gene of the 1D3 antibody which recognizes mouse CD19 was cloned according to standard methods from rat hybridoma 1D3 (ATCC® HB-305™) commercially available from ATCC. The cloned L-chain variable region was linked with the mouse kappa chain constant region. The cloned H-chain variable region was linked with the modified constant region sequence indicated below. For the H-chain constant region, firstly, to promote heterologous formation of the Fc region, the CH3 domain D399R is introduced into the Fc region mF 18 which has been introduced with amino acid mutations to lose the binding to the Fc receptors (i.e., carrying amino acid mutations where Pro at position 235 according to EU numbering is substituted with Lys and Ser at position 239 is substituted with Lys). Furthermore, the sequences of V5 tag for use in detection and purification and the third TB domain (TGFbeta binding domain) (TB3) of the mouse LTBP1 protein (SEQ ID NO: 9) for the conjugation of latent TGFβ3 was linked to the C terminal side. The above-mentioned mutations for not binding to Fc receptors and K409E as mutation to promote heterologous formation were also introduced into the H chain constant region that only has the Fc region (SEQ ID NO: 10). Details on the mutations for not binding to Fc receptors are described in published patent WO 2012-132067, and details on the mutations to promote heterologous formation are described in published patent WO2015-046467.
These genes were cloned into a pBEF-OriP vector for transient expression in mammalian cells (Wako). Transfection-grade samples were prepared from the obtained plasmids using a plasmid preparation kit (Macherey-Nagel, NucleoBond Xtra Maxi), and they were used for the expression experiments. The gene names and protein names of the expressed proteins are shown in Table 1.
Expi293-F cells (Life technologies, A14527) and a transfection kit (ExpiFectamine293 transfection kit) therefor were used to express these proteins. Expi293-F cells were cultured using the Expi293 medium (Life technologies) in a CO2 incubator at 37° C. by shaking at 135 rpm. Plasmids were introduced according to the protocol by Life technologies, and in addition to TGFβ3 and antibody plasmids, pBEF-EBNA1 was added. The enhancer solution included in the kit was not used. As a result of examination, the culturing period was set to 5 or 7 days. After completion of culturing, the culture was centrifuged, and the supernatant was filtered through a 0.45-μm filter. The obtained culture supernatant was frozen in liquid nitrogen, and then stored in a −80° C. freezer.
Latent TGFβ3 was expressed using a ssIgK-FLAG-TGFbeta3(C25S) construct, and by co-expressing 30 μg of the plasmid and 2.4 μg of pBEF-EBNA1 per 30 mL of culture. Since maximum was reached with a culture period of seven days, the subsequent experiments were carried out by culturing for seven days. The percentage of the Pro-form increased when the Enhancer 1 and 2 solutions included in the transfection kit were added; therefore, they were not used.
AKTA avant (GE Healthcare) was used to apply 200 mL of the culture supernatant onto a column packed with 2 mL of FLAG-M2 resin (anti-FLAG M2 agarose affinity gel #A2220 from Sigma) which had been equilibrated with a 50 mM HEPES/150 mM NaCl/1 mM EDTA solution at pH 7.8. The experiment was performed in a cold room. After application at a flow rate of 1 ml/min, the column was washed using an equilibration buffer. Elution was performed using an equilibration buffer containing 0.1 mg/ml FLAG peptide (#F3290 from Sigma). The fractions containing latent-TGFβ3 were combined and dialyzed against a 20 mM Tris-HCl, pH8.0/1 mM EDTA solution. The dialyzed fraction was adsorbed onto an ENrich-Q column (10×100 mm #780-0003 from BioRad), and then eluted with a NaCl solution using a concentration gradient of 0-300 mM/45 CV. When the separation from the Pro-form was not satisfactory, further purification was undertaken using a RESOURCE-Q 1 ml column (#17-1177-01 from GE healthcare). After separation by an ion-exchange column, the sample was concentrated using an ultrafiltration membrane, and this was purified through a Superdex 200 increase 10/300 gel filtration column (#28-9909-44 from GE healthcare). The gel filtration chromatogram of latent-TGFβ3 is shown in
The fractionated fractions were analyzed by SDS-PAGE. 10-20% gradient gels or 12.5% gels from DRC were used, and reducing or non-reducing reagents from Nacalai were used for the sample buffer. A sample buffer was added at one-third of the volume of each of the fractions, and then this was subjected to heat treatment at 95° C. for five minutes to prepare samples for electrophoresis. Protein marker (PrecisionPlus protein All blue standards #161-0373) from BioRad was used as the molecular weight marker. Images of electrophoresis of the gel filtration fractions are shown in
The TGFβ3-modified antibody molecule (1D3-mF 18-latent TGFβ3) and the modified antibody molecule (1D3-mF 18) were expressed using the plasmids inserted with the genes shown in Table 1. Both molecules used the same plasmids for the antibody H chain and L chain, and expression of the TGFβ3-modified antibody molecule involved co-expression of the TGFβ3 expression plasmid for conjugation to the C terminal side of the antibody. Expression conditions were examined to optimize the expression of the conjugate. Table 2 shows the amount of plasmids used for the expression. The ratio of the amount of TGFβ3 plasmid to the antibody was examined by increasing it from one equivalent to two-fold, and up to five-fold, and as a result, the conjugate was found to be maximized at two-fold, and the binding ratio was found to be maximized at 5-fold the amount of the antibody (
A single-arm antibody and an ordinary antibody (2 arms) were expressed with a TGFβ3 to antibody plasmid ratio of 2:1 or 5:1. For every 100 mL of the obtained culture supernatant, 1 mL of antiV5-tag resin (V5-tagged protein purification gel #3316 from MBL) equilibrated with PBS was added, and the antibodies were adsorbed onto the resin by shaking at 4° C. for 15 hours. This resin was packed into a 10-mL centrifuge column (PIERCE), and then washed with PBS using ten-times the column volume. Elution was performed with one column volume of 2 mg/mL of the V5 peptide in PBS (V5-tag peptide #3315-205 from MBL) for 30 minutes at room temperature. This was repeated five times to obtain the eluate. This eluate was concentrated using an ultrafiltration membrane (Amicon Ultra MWCO10K, #UFC901024 or #UFC801024 from Millipore), and then applied to a gel filtration column.
The gel filtration purification was carried out on an AKTA avant purification system (GE Healthcare), using a Superdex 200 increase 10/300 (#28-9909-44 from GE healthcare) column. PBS was used for the equilibration buffer. A gel filtration chromatogram of the single arm 1D3-mF 18-latent TGFβ3 conjugate is shown in
As a result of electrophoresis (
The biological activities of the prepared latent TGFβ3 and the TGFβ3-modified antibody molecules (single arm 1D3-mF18-latent TGFβ3 conjugate or single arm 1D3-mF18 without conjugation of TGFβ3) were confirmed using HEK-Blue_TGFb cells (hkb-tgfb, InvivoGen). Regarding the evaluation method for biological activity of mature TGFβ3 released by acid treatment or protease treatment, input of the Smad signal was confirmed by evaluating the secretory alkaline phosphatase (SEAP) activity.
Samples prepared by adding 5 μg/mL of the Plasmin (P1867, Sigma) protease to latent TGFβ3 or TGFβ3-modified antibody molecule, and mature TGFβ3 recombinant protein (243-B3-010/CF, R&D systems) dissolved in 4 mM HCl, which was used as the standard, were dispensed into a flat-bottom 96-well plate, the HEK-Blue_TGFb cell suspension solution was added at 5×104 cells/well, and the cells were cultured overnight (20 hours) at 37° C. in a CO2 incubator. On the following day, 180 μL of the QUANTI-Blue (rep-qb1, InvivoGen) chromogenic substrate was added to 20 μL of the cell culture supernatant, and after incubating for one hour at 37° C. in a CO2 incubator, the secretory alkaline phosphatase (SEAP) activity was measured by VersaMax spectrometer (Molecular devices) at OD 655 nm.
While the EC50 of the mature TGFβ3 recombinant protein was approximately 0.2 ng/mL, the plasmin protease-treated latent TGFβ3 and the TGFβ3-modified antibody molecule (1D3-mF 18-latent TGFβ3) showed biological activities with an EC50 value of approximately 10 ng/mL or so. On the other hand, the antibody molecule with no conjugated TGFβ3 (1D3-mF18) did not show any biological activity even when treated with the plasmin protease (
Binding specificity to B-cell of the TGFβ3-modified antibody molecule was examined by FACS analysis. Spleen was isolated from 10-14-week-old male C57BL/6N mice purchased from Japan Charles River. Splenocytes were prepared and resuspended in FACS buffer, and were reacted with the TGFβ3-modified antibody molecule and fluorescence-labeled antibodies against markers for T cells, B cells, NK cells, monocytes, dendritic cells, and such. The following cell surface markers were used as indicators: B220 (BUV395, 563793, BD) and CD138 (APC, 132506, Biolegend) for specificity to B cells; CD3e (BUV737, 564618, BD), CD4 (PE-CF594, 562285, BD), CD8 (PE-Cy7, 552877, BD), and CD25 (APC, 102012, Biolegend) for T cells; CD11b (PE, 553311, BD), CD11c (APC, 550261, BD), and Gr-1 (FITC, 553127, BD) for lymphoid DC cells, plasmacytoid DC cells, myeloid DC cells, and macrophages; and CD11b (PE, 553311, BD) and CD49b (DX5) (BV421, 563063, BD) for NK cells; and fluorescence-labeled antibodies that recognize the respective antigens were combined. Subsequently, an antibody that recognizes the V5 tag conjugated to TGFβ3-modified antibody molecule (rabbit anti-V5 Ab, V8137, Sigma) and BV421-conjugated donkey anti-rabbit IgG Ab (406410, Biolegend) were individually reacted at 4° C. for 30 minutes, washed twice using a FACS buffer, and then, those cells were fractionated using a FACS analyzer (LSRFortessaX-20, BD) to confirm the cell specificity of the TGFβ3-modified antibody molecule.
As a result of FACS analysis, since the splenocytes were not from disease models, staining of CD138-positive plasma cells could not be evaluated; however, binding specificity to B220-expressing B cells could be confirmed (
The biological activity to actually input Smad signaling of the TGFβ3-modified antibody molecule which was confirmed to specifically bind to B cells was evaluated by detection of phosphorylated Smad2/3. Spleen was isolated from 10-14-week-old male C57BL/6N mice purchased from Japan Charles River. Splenocytes were prepared and resuspended in PBS containing 0.5% BSA; latent TGFβ3, the TGFβ3-modified antibody molecule, and 5 μg/mL of Plasmin protease were added and incubated for 30 minutes at 37° C. in a CO2 incubator; then the cells were fixed with BD Phosflow™ Lyse/Fix buffer (558049, BD); and after washing twice, cell membrane was perforated by BD Phosflow™ Perm buffer III (558050, BD) and stained with PE-labeled anti-phosphorylated Smad2/3 antibody (562586, BD Phosflow™ Smad2 (pS465/pS467)/Smad3 (pS423/pS425), BD), a fluorescence-labeled antibody against B220 (BUV395, 563793, BD), and a fluorescence-labeled antibody against CD4 (PE-CF594, 562285, BD). Phosphorylated Smad2/3 in B cells were evaluated using a FACS analyzer, and the activity to input Smad signaling of the TGFβ3-modified antibody molecule was assessed.
As a result, when compared to no stimulation, mature TGFβ1 and mature TGFβ3 increased the proportion of phosphorylated Smad2/3; Plasmin-treated latent TGFβ3 and the TGFβ3-modified molecule increased the proportion of phosphorylated Smad2/3 similarly. On the other hand, 1D3-mF 18 unconjugated with TGFβ3 or the plasmin protease alone did not affect the proportion of phosphorylated Smad2/3 compared to the no stimulation (
Spleen was isolated from 10-14-week-old male C57BL/6N mice purchased from Japan Charles River, and fractionated B cells (negative fraction) were purified using a Mouse B cell isolation kit (130-090-862, Miltenyi Biotec). Reactions were carried out using the CellTrace™ CFSE (Carboxyfluorescein diacetate succinimidyl ester) Cell Proliferation Kit for Flow Cytometry (C34554, Molecular Probes) for 20 minutes in a 37° C. water bath, and then the cells were washed twice with PBS, and dispensed into a round-bottom 96-well plate at 10,000 cells/well. Then, latent TGFβ3, the TGFβ3-modified antibody molecule, and 0.5 μg/mL of the Plasmin protease were added. Furthermore, for stimulation of cell proliferation, 5 μg/mL of anti-IgM (715-005-140, Jackson), 5 μg/mL of anti-CD40 (HM40-3, BD Pharmingen), and 2 ng/mL of recombinant murine IL-4 (214-14, Peprotech) were added, and after culturing for three days at 37° C. in a CO2 incubator, the B cell proliferation-suppressive effect of the TGFβ3-modified antibody molecule was verified using a FACS analyzer (LSRFortessaX-20, BD) by examining cell division. A mature TGFβ1 recombinant protein (240-B-010/CF, R&D Systems) and a mature TGFβ3 recombinant protein (243-B3-010/CF, R&D Systems) were used as controls, and stimulation was started at the same time as antibody molecules.
While the B cell proliferation-suppressive effect of mature TGF 31 was weak, the B cell proliferation-suppressive effect was confirmed for plasmin protease-treated TGFβ3-modified antibody molecule and also for latent TGFβ3, in a similar manner to mature TGFβ3 (
Because of the molecular properties, mature and latent TGFβ3 are predicted to show non-specific binding and a very rapid elimination rate in blood, and it is assumed that development as pharmaceutical agents in their original molecular form will face many problems. To sustainably suppress activated B cells, the molecular form of a TGFβ3-modified antibody molecule was examined to see whether blood half-life can be prolonged.
Latent TGF-β3 and the TGF-β3-modified antibody molecule were administered at 1 mg/kg to 6-week-old male C57BL/6J mice purchased from Japan Charles River through the caudal vein. After administration, blood was collected over time from the jugular vein, and plasma samples were obtained by subjecting the blood to centrifugation. The TGF-β3-modified antibody molecule and TGF-β3 concentrations in the plasma samples were quantified by ELISA. The concentration data of TGF-β3 and the TGF-β3-modified antibody molecule in plasma were analyzed, and the area under the plasma concentration curve (AUCinf) and the half-life (T1/2) were calculated.
The AUC and half-life of the antibody portion of the TGF-β3-modified antibody molecule were 8100 ng-day/mL and 2.09 day, respectively. On the other hand, the AUCinf of TGF-β3 was 146 ng-hour/mL when administered as latent TGFβ3, but 982 ng-hour/mL when administered as a TGFβ3-modified antibody molecule. Furthermore, T1/2 of TGF-β3 was 0.116 hours when administered as latent TGFβ3, but 2.44 hours when administered as a TGF-β3-modified antibody molecule. This study revealed that administration of the TGF-β3—modified antibody molecule increases AUC and prolongs the T1/2(
These results suggest that modification to produce the molecular form of a TGFβ3-modified antibody molecule enables sustained prolongation of the Smad signal input effect as compared with latent TGFβ3, and suggests its possibility as a therapeutic agent.
The specific activity of the TGFβ3-modified antibody molecule to B cells will be evaluated by the following methods:
The spleen and lymph nodes are isolated from B6.Cg-Tg(SBE/TK-luc)7Twc/J mice (SBE-Luc Tgm, 005999, Jackson Laboratory). They are reacted with the TGFβ3-modified antibody molecule and fluorescence-labeled antibodies against markers for T cells, B cells, NK cells, monocytes, dendritic cells, and such to confirm B cell specificity. Furthermore, the plasmin protease are added to the purified B cells to measure the luciferase activity. This way, intracellular signals induced by TGFβ3 will be evaluated.
An Alexa Fluor 647-labeled TGFβ3-modified antibody molecule is administered to SBE-Luc Tg mice, and in vivo imaging will be performed using IVIS Spectrum CT (Perkin Elmer). By using fluorescent signals to confirm that the distribution of antibodies and distribution from fluorescent signals of Smad signals mediated by TGFb3 overlap in vivo, the concept of the TGFβ3-modified antibody molecule, i.e., recruitment to B cells and the Smad signal input effect, will be confirmed.
Four proteins are prepared, which are 1D3-mF 18, 1D3-mF18-latent TGFb3, and latent-TGFb3 shown in the above-mentioned Examples, as well as a modified antibody molecule that is linked with latent TGFb3 and having an antibody (different from the anti-CD19 antibody (1D3)) that does not bind to the B cell surface. These are administered to C57BL/6N mice or SBE-Luc Tg mice through the caudal vein, and the spleen and lymph nodes are isolated to compare and examine the proportions of pSmad. Furthermore, the four types of proteins mentioned above are administered through the caudal vein, and after isolating the spleen and lymph nodes, fluorescence-labeled antibodies against markers of T cells, B cells, NK cells, monocytes, dendritic cells, and such are used as indicators to isolate the respective cells and extract their RNAs. Then, by comprehensively analyzing the expressed genes using a next-generation sequencer, changes in expression of the TGFβ3 signal-related genes in the respective cells will be evaluated to confirm the concept of the TGFβ3-modified antibody molecule.
The above-mentioned evaluation prove that the TGFβ3-modified antibody molecule has an activity specific to the targeted B cells.
The activity of TGF-03 to suppress B cell activation was newly found in the present invention, and the invention provides novel therapeutic strategies that use this activity for autoimmune diseases.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2014-241193 | Nov 2014 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2015/065466 | 5/28/2015 | WO | 00 |
